174 related articles for article (PubMed ID: 16153607)
21. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.
Rivière C; Richard T; Quentin L; Krisa S; Mérillon JM; Monti JP
Bioorg Med Chem; 2007 Jan; 15(2):1160-7. PubMed ID: 17049256
[TBL] [Abstract][Full Text] [Related]
22. Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro.
Gupta VB; Rao KS
Neurosci Lett; 2007 Dec; 429(2-3):75-80. PubMed ID: 18023978
[TBL] [Abstract][Full Text] [Related]
23. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42).
Lee KH; Shin BH; Shin KJ; Kim DJ; Yu J
Biochem Biophys Res Commun; 2005 Mar; 328(4):816-23. PubMed ID: 15707952
[TBL] [Abstract][Full Text] [Related]
24. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease.
Ono K; Yoshiike Y; Takashima A; Hasegawa K; Naiki H; Yamada M
J Neurochem; 2003 Oct; 87(1):172-81. PubMed ID: 12969264
[TBL] [Abstract][Full Text] [Related]
25. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta.
Ono K; Naiki H; Yamada M
Curr Pharm Des; 2006; 12(33):4357-75. PubMed ID: 17105432
[TBL] [Abstract][Full Text] [Related]
26. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Yamada M; Naiki H
Biol Psychiatry; 2002 Nov; 52(9):880-6. PubMed ID: 12399141
[TBL] [Abstract][Full Text] [Related]
27. Binding of trypsin to fibrillar amyloid beta-protein.
Chander H; Chauhan A; Wegiel J; Malik M; Sheikh A; Chauhan V
Brain Res; 2006 Apr; 1082(1):173-81. PubMed ID: 16510132
[TBL] [Abstract][Full Text] [Related]
28. Characterizations of distinct amyloidogenic conformations of the Abeta (1-40) and (1-42) peptides.
Lim KH; Collver HH; Le YT; Nagchowdhuri P; Kenney JM
Biochem Biophys Res Commun; 2007 Feb; 353(2):443-9. PubMed ID: 17184733
[TBL] [Abstract][Full Text] [Related]
29. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.
Necula M; Breydo L; Milton S; Kayed R; van der Veer WE; Tone P; Glabe CG
Biochemistry; 2007 Jul; 46(30):8850-60. PubMed ID: 17595112
[TBL] [Abstract][Full Text] [Related]
30. Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils.
Cui L; Zhang Y; Cao H; Wang Y; Teng T; Ma G; Li Y; Li K; Zhang Y
J Alzheimers Dis; 2013; 37(1):19-28. PubMed ID: 23727899
[TBL] [Abstract][Full Text] [Related]
31. Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils.
Byeon SR; Jin YJ; Lim SJ; Lee JH; Yoo KH; Shin KJ; Oh SJ; Kim DJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):4022-5. PubMed ID: 17544669
[TBL] [Abstract][Full Text] [Related]
32. Early detection of amyloid aggregation using intrinsic fluorescence.
Rolinski OJ; Amaro M; Birch DJ
Biosens Bioelectron; 2010 Jun; 25(10):2249-52. PubMed ID: 20362424
[TBL] [Abstract][Full Text] [Related]
33. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin.
Sakono M; Zako T; Ueda H; Yohda M; Maeda M
FEBS J; 2008 Dec; 275(23):5982-93. PubMed ID: 19021772
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones.
Ikeda K; Okada T; Sawada S; Akiyoshi K; Matsuzaki K
FEBS Lett; 2006 Dec; 580(28-29):6587-95. PubMed ID: 17125770
[TBL] [Abstract][Full Text] [Related]
35. Model of Alzheimer's disease amyloid-beta peptide based on a RNA binding protein.
Mathura VS; Paris D; Ait-Ghezala G; Quadros A; Patel NS; Kolippakkam DN; Volmar CH; Mullan MJ
Biochem Biophys Res Commun; 2005 Jul; 332(2):585-92. PubMed ID: 15896718
[TBL] [Abstract][Full Text] [Related]
36. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein.
Akaishi T; Morimoto T; Shibao M; Watanabe S; Sakai-Kato K; Utsunomiya-Tate N; Abe K
Neurosci Lett; 2008 Oct; 444(3):280-5. PubMed ID: 18761054
[TBL] [Abstract][Full Text] [Related]
37. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
[TBL] [Abstract][Full Text] [Related]
38. A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation.
Dolphin GT; Chierici S; Ouberai M; Dumy P; Garcia J
Chembiochem; 2008 Apr; 9(6):952-63. PubMed ID: 18330854
[TBL] [Abstract][Full Text] [Related]
39. Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component.
Okada T; Wakabayashi M; Ikeda K; Matsuzaki K
J Mol Biol; 2007 Aug; 371(2):481-9. PubMed ID: 17582434
[TBL] [Abstract][Full Text] [Related]
40. Conversion of non-fibrillar beta-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation.
Benseny-Cases N; Cócera M; Cladera J
Biochem Biophys Res Commun; 2007 Oct; 361(4):916-21. PubMed ID: 17679138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
